The presentations follow Ashvattha's recent announcement of up to $50 million in additional Series B financing led by Tribe Capital to advance the company's hydroxyl dendrimer therapeutic (HDT) ...

class of antidiabetic drugs, which include rosiglitazone and pioglitazone 4,5. PPAR-γ is prominently expressed in activated monocytes and tissue macrophages in vivo, including the foam cells of ...

Currently, the most accepted model of macrophage classification describes several polarization statuses between two extreme populations: the M1-like or pro-inflammatory, and the M2-like or ...

PagerDuty, Inc. , a global leader in digital operations management, announced today the appointment of David Williams as Senior Vice President of Product. Williams will lead all products and core ...

Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based ...

CATUMAXOMAB BECOMES THE ONLY APPROVED DRUG THERAPY FOR MALIGNANT ASCITES, A RARE AND DEBILITATING COMPLICATION OF ADVANCED-STAGE CANCER UNDER A LICENSING AGREEM ...

Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...

Antitumor functions of AMs have been described in non-small cell lung cancer (NSCLC) (7), but once integrated within solid tumors, they become a component of a heterogenous class of tumor-associated ...

At closing of the transaction, JASMIN shall acquire Pierre Fabre's R&D Centre (including R&D Site and R&D activities) at Saint-Julien-en-Genevois, France, and JBIRSPL would also execute a Shareholders ...

Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development collaboration with Toray Industries, Inc. is Caprin-1, a novel cancer target discovered by Toray. The ...